Pancreatic Cancer Research

ResearcherTohoku UniversityActive in the last 2 years

Masakazu Yamamoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6027-620X; OpenAlex author ID A5001076934. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
50
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: 3 papers · 2019: 1 paper · 2020: 1 paper · 2021: 5 papers · 2022: 2 papers · 2023: none · 2024: none · 2025: 1 paper

Papers 17

  1. Clinicopathological Relevance of SMAD4 and RUNX3 in Patients With Resected Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002429↗
  2. Outcomes of lung metastasis from pancreatic cancer: A nationwide multicenter analysis. Last author DOI 10.1002/jhbp.1127↗
  3. Whole-exome Sequencing Reveals New Potential Susceptibility Genes for Japanese Familial Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000004213↗
  4. Impact of the controlling nutritional status score on severe postoperative complications of pancreaticoduodenectomy for pancreatic cancer. Last author DOI 10.1007/s00423-021-02151-7↗
  5. Evaluation of the validity of pancreatectomy for very elderly patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00423-021-02170-4↗
  6. Evaluation of the significance of adjuvant chemotherapy in patients with stage ⅠA pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2021.01.024↗
  7. Left-sided Portal Hypertension After Pancreaticoduodenectomy With Resection of the Portal Vein/Superior Mesenteric Vein Confluence in Patients With Pancreatic … Co-author DOI 10.1097/sla.0000000000003487↗
  8. Evaluation of Early Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Receiving Gemcitabine Together With Nab-paclitaxel. Last author DOI 10.21873/cdp.10053↗
  9. Is the New T1 Category as Defined in the Eighth Edition of the AJCC Pancreatic Cancer Staging System an Improvement? Co-author DOI 10.1007/s11605-019-04464-x↗
  10. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma. Last author DOI 10.1080/00365521.2019.1624816↗
  11. Multinational validation of the American Joint Committee on Cancer 8th edition pancreatic cancer staging system in a pancreas head cancer cohort. Co-author DOI 10.1002/jhbp.577↗
  12. Resection for recurrent pancreatic cancer in the remnant pancreas after pancreatectomy is clinically promising: Results of a project study for pancreatic surge… Co-author DOI 10.1016/j.surg.2018.05.050↗
  13. Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-018-26526-x↗
  14. [Symptoms, clinical findings and laboratory data in the pancreatic ductal adenocarcinoma]. Last author PMID 25856995↗
  15. Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients. Last author DOI 10.4161/onci.27010↗
  16. Targeting of MAPK-associated molecules identifies SON as a prime target to attenuate the proliferation and tumorigenicity of pancreatic cancer cells. Co-author DOI 10.1186/1476-4598-11-88↗
  17. Impact of dihydropyrimidine dehydrogenase and γ-glutamyl hydrolase on the outcomes of patients treated with gemcitabine or S-1 as adjuvant chemotherapy for adv… Last author DOI 10.3892/etm.2011.340↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Toru Furukawa · 9 shared papers, 2012–2025 · strength 1.27
  2. Wataru Izumo · 5 shared papers, 2019–2021 · strength 0.67
  3. Masahiro Shiihara · 5 shared papers, 2019–2021 · strength 0.67
  4. Hiroki Yamaue · 3 shared papers, 2018–2022 · strength 0.33
  5. Katsuya Hirose · 1 shared paper, 2025 · strength 0.33
  6. Yuko Omori · 1 shared paper, 2025 · strength 0.33
  7. Shugo Mizuno · 2 shared papers, 2021–2022 · strength 0.24
  8. Masayuki Sho · 2 shared papers, 2021–2022 · strength 0.24
  9. Tsutomu Fujii · 2 shared papers, 2018–2021 · strength 0.22
  10. Takashi Hatori · 4 shared papers, 2011–2015 · strength 0.19
  11. Jae Ri Kim · 2 shared papers, 2018–2020 · strength 0.17
  12. Seungyeoun Lee · 2 shared papers, 2018–2020 · strength 0.17
  13. Jin Peng He · 2 shared papers, 2018–2020 · strength 0.17
  14. Hongbeom Kim · 2 shared papers, 2018–2020 · strength 0.17
  15. Christopher Lee Wolfgang · 2 shared papers, 2018–2020 · strength 0.17
  16. Jin‐Young Jang · 2 shared papers, 2018–2020 · strength 0.17
  17. Sun‐Whe Kim · 2 shared papers, 2018–2020 · strength 0.17
  18. Wooil Kwon · 2 shared papers, 2018–2020 · strength 0.17
  19. Erina Takai · 1 shared paper, 2022 · strength 0.13
  20. Akihiro Ohmoto · 1 shared paper, 2022 · strength 0.13
  21. Junji Furuse · 1 shared paper, 2022 · strength 0.13
  22. Shinichi Yachida · 1 shared paper, 2022 · strength 0.13
  23. Chigusa Morizane · 1 shared paper, 2022 · strength 0.13
  24. Yoshiaki Murakami · 1 shared paper, 2021 · strength 0.13
  25. Sohei Satoi · 1 shared paper, 2021 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.